Article citationsMore>>

Subramanian, J., Katta, A., Masood, A., Vudem, D.R. and Kancha, R.K. (2019) Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers. The Oncologist, 24, e1303-e1314.
https://doi.org/10.1634/theoncologist.2018-0845

has been cited by the following article:

• TITLE: Antibody-Coupled Drugs in HER2-Positive Gastric Cancer

  AUTHORS: Baofeng Liu, Yuanmei Dai, Xiaohui Shen, Xiangyang Tian

  KEYWORDS: Antibody-Coupled Drugs, HER2-Positive Gastric Cancer, Review

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.7, July 7, 2023

  ABSTRACT: Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic drugs with antibody drugs through a linker. Antibody drug conjugates combine the targeting characteristics of traditional antibody drugs with the cytotoxic characteristics of small molecule drugs, while reducing the side effects of both drugs, making them a kind of “biological missile” and representing a relatively new and evolving class of anti-cancer drugs. Antibody-coupled drugs are currently used in many solid tumors, and this article reviews the clinical application of antibody-coupled drugs in HER2-positive gastric cancer.